Search Results

You are looking at 1 - 3 of 3 items for

  • Author: Ēriks Jākobsons x
Clear All Modify Search
Open access

Aris Lacis, Inta Bergmane, Valts Ozolins, Inguna Lubaua, Valerija Groma, Elina Ligere, Eriks Jakobsons and Andrejs Erglis

First Results of using Stem Cell Transplantation for Pediatric Patients in Case of Dilated Cardiomyopathy

Introduction. Dilated cardiomyopathy is a serious disorder of the myocardium in pediatric age. Conservative therapy is limited and lethal outcome observed in one third of patients within a year. Bone marrow derived progenitor cell transplantation is becoming a promising method of treatment in adult population and there is ground to believe there are perspectives in pediatric cardiology.

Aim of the Study. We present the first results of bone marrow cell transplantation in case of dilated cardiomyopathy for six patients at age four months to seventeen years.

Materials and methods. We did the six Bone marrow derived progenitor cell (BMCs) intramycardial transplantations. Five to 30 mililiters of bone marrow were aspirated from iliac bone. Seventeen to 90 million BMCs were isolated and as suspension of physiologic saline given to patients by intramyocardial punction. Every patient underwent repeated examination every two month.

Results. Six months following bone marrow derived progenitor stem cell intramyocardial transplantation we observed increase of ejection fraction in 4 patients, decrease of dilatation echocardiographycally and cardiothoracic ratio (CTR) at chest x-ray; decrease of the stage of heart insufficiency clinically from class IV to I-II(NYHA).

Conclusions. We see the intramyocardial administration of bone marrow cells proved to be technically feasible and safe, also the procedure does not need for expensive technical equipment. The bone marrow transplantation improves the patients clinical situation and physical measurements. Our method might be used for the stabilization of the patient to get the time for further treatment.

Open access

Valdis Gončars, Konstantīns Kalnbērzs, Ēriks Jākobsons, Ieva Briede, Kristaps Blūms, Kristaps Ērglis, Mārtiņš Ērglis, Liene Patetko, Indriķis Muižnieks and Andrejs Ērglis

Abstract

The clinical effects on knee osteoarthritis (OA) symptoms and tissue structure were evaluated after bone marrow-derived mononuclear cell intraarticular injection. A group of 32 patients with 34 knee joints in stage II–III osteoarthritis were treated by intraarticular injection of mononuclear cell suspension. Clinical results were obtained by KOOS (Knee Osteoarthritis Outcome Score) and KSS (Knee Society Score) scores during a 12 months follow-up period. Radiological evaluation was performed using magnetic resonance imaging. A comparison with a control group of 28 patients treated with routinely used three hyaluronic acid intra-articular injections was made. No adverse effects were observed after the bone marrow derived mononuclear cells (BM-MNC) injection. At the end point of the follow up all score results had improved, compared to those at to the starting point. 65% of patients maintained minimal perceptible clinical improvement of the score results. The Whole Organ Magnetic Resonance Imaging Score showed improvement from 44.31 to 42.93 points (p < 0.05) during a 6–7 month period. Comparing score results to the control group, a statistically significant (p < 0.05) improvement in the KOOS pain subscale score at the 6 and 12 months was observed in the mononuclear cell group. BM-MNC injection leads to a decrease of knee OA symptoms and slows changes in structure of the degenerative joint tissue.

Open access

Kristaps Erglis, Iveta Mintale, Ieva Briede, Aldis Rozenbergs, Sanda Jegere, Inga Narbute, Eriks Jakobsons, Vilnis Dzerve, Martins Erglis, Iveta Bajāre and Andrejs Erglis

Abstract

Objective: To evaluate the impact of two original compositions of polyphenols-containing dietary supplement on lipid profile and level of C-reactive protein (CRP) in patients with angiographycally verified coronary artery disease (CAD). Design and methods: 167 patients were selected during their scheduled post-event elective bicycle stress-test examination. All patients received standard CAD therapy and permanent statin therapy and had elevated total cholesterol (TC > 5.0 mmol/L) and/or CRP (>3.5 mg/L) levels. The study consisted of 2 days of polyphenol depletion followed by a 12-week supplementation period in a randomized, blinded, placebo-uncontrolled parallel design. Two different compositions SILVA 1 (Quercetine, linseed oil and Resveratrol), and SILVA 2 (Quercetine, linseed oil and Pycnogenol) were tested. Results: All parameters changed compared baseline and 1 and 3 months in both groups. CRP decreased from 2.48 ± 1.62 mg/L at baseline to 1.97 ± 1.15 mg/L, high density cholesterol (HDL-C) increased from 1.18 ± 0.31 to 1.38 ± 0.34 mmol/L, also decrease of triglycerides (TG) from 1.5 to 1.29 mmol/L after 3 months treatment in SILVA I group was statistically significant (p < 0.001). Changes of parameters between baseline and 1 or 3 months in SILVA II group were not statistically significant. Hovewer, decrease of CRP (from 2.6 ± 1.28 to 2.41 ± 1.68), decrease of low density cholesterol (LDL-C from 2.95 ± 1.2 to 2.88 ± 1.21), increase of HDL-C (from 1.25 ± 0.22 to 1.34 ± 0.23), decrease of TC (from 5.2 ± 1.3 to 5.1 ± 1.28) and decrease of TG (from 1.4 ± 0.41 to 1.3 ± 0.38) can be counted as tendency of changes. Conclusion: This study reveals the superiority of treatment with statins in combination with composition containing Resveratrol for correction of lipid profile and inflamation marker CRP of patients with CAD